Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice

Diabetes, Obesity and Metabolism

Volumn 12, Issue 3, 2010, Pages 234-245

  Perreault, M ^a   Will, S ^a   Panza, D ^a   Gareski, T ^a   Harding, K ^a   Kubasiak, D ^a   Jalenak, M ^a   Gartrell, K ^a   Wang, S ^a   Bollag, G ^b   Artis, D R ^b   Ibrahim, P N ^b   Womack, P ^b   Lin, J J ^b   Saiah, E ^a   Mansour, T S ^a   Vlasuk, G P ^a   Erbe, D V ^a   Tobin, J F ^a  

^a PFIZER INC   (United States)

^b PLEXXIKON INC   (United States)

Author keywords

Appetite suppression; Obesity; PPAR pan agonism

Indexed keywords

ACYLCARNITINE; CELL NUCLEUS RECEPTOR; DEXFENFLURAMINE; GLUCOSE; INSULIN; KETONE BODY; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHENYLACETIC ACID DERIVATIVE; ROSIGLITAZONE; TRIACYLGLYCEROL; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPETITE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE METABOLISM; HISTOPATHOLOGY; KNOCKOUT MOUSE; LIPID METABOLISM; LIPID OXIDATION; LIVER NECROSIS; LIVER PARENCHYMA; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE REGENERATION; NONHUMAN; OBESITY; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SKELETAL MUSCLE; TISSUE DISTRIBUTION; WEIGHT REDUCTION;

EID: 75649125644     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01157.x     Document Type: Article

References (41)

1. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-1199.
2. Elangbam CS, Tyler RD, Lightfoot RM. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation -an update. Toxicol Pathol 2001, 29:224-231.
3. Fruchart JC. Novel peroxisome proliferator activated receptor-alpha agonists. Am J Cardiol 2007, 100:n41-n46.
4. Scharrer E. Control of food intake by fatty acid oxidation and ketogenesis. Nutrition 1999, 15:704-714.
5. Chaput E, Saladin R, Silvestre M, Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 2000, 271:445-450.
6. Keech A, Simes RJ, Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
7. Staels B, Dallongeville J, Auwerx J. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
8. Mancini FP, Lanni A, Sabatino L. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett 2001, 491:154-158.
9. Schwartz GJ, Fu J, Astarita G. Cell Metab 2008, 8:281-288. The lipid messenger OEA links dietary fat intake to satiety.
10. Fu J, Gaetani S, Oveisi F. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003, 425:90-93.
11. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590-597.
12. Wang YX, Lee CH, Tiep S. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
13. Wang YX, Zhang CL, Yu RT. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004, 2:e294.
14. Arsenijevic D, de Bilbao F, Plamondon J. Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J Cereb Blood Flow Metab 2006, 26:433-445.
15. Harrington WW, SB C, GW J. The effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice. PPAR Res 2007, 2007:97125.
16. de Souza CJ, Eckhardt M, Gagen K. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001, 50:1863-1871.
17. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999, 22:288-293.
18. Miyazaki Y, Mahankali A, Matsuda M. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87:2784-2791.
19. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
20. Wilding J. Thiazolidinediones, insulin resistance and obesity: finding a balance. Int J Clin Pract 2006, 60:1272-1280.
21. Yamauchi T, Kamon J, Waki H. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001, 276:41245-41254.
22. Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 2005, 48:96-104.
23. Jiang G, Dallas-Yang Q, Li Z. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes 2002, 51:2412-2419.
24. Artis DR, Lin JJ, Zhang C. Proc Nat Acad Sci USA 2009, 106:262-267. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.
25. Erbe DV, Gartrell K, Zhang YL. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006, 45:154-162.
26. Erbe DV, Wang S, Zhang YL. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol Pharmacol 2005, 67:69-77.
27. Koves TR, Ussher JR, Noland RC. Cell Metab 2008, 7:45-56. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance.
28. Pruimboom-Brees I, Haghpassand M, Royer L. A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis. Am J Pathol 2006, 169:750-760.
29. Perreault M, Erbe D, Tobin J. PPARδ agonism for the treatment of obesity and associated disorders: challenges and opportunities. PPAR Res 2008, 2008:125387.
30. Tanaka T, Yamamoto J, Iwasaki S. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003, 100:15924-15929.
31. Langhans W, Pantel K, Scharrer E. Ketone kinetics and D- (-)-3-hydroxybutyrate-induced inhibition of feeding in rats. Physiol Behav 1985, 34:579-582.
32. Langhans W, Wiesenreiter F, Scharrer E. Different effects of subcutaneous d,l-3-hydroxybutyrate and acetoacetate injections on food intake in rats. Physiol Behav 1983, 31:483-486.
33. Sun M, Martin RJ, Edwards GL. ICV beta-hydroxybutyrate: effects on food intake, body composition, and body weight in rats. Physiol Behav 1997, 61:433-436.
34. Dhillo WS. Appetite regulation: an overview. Thyroid 2007, 17:433-445.
35. Chakravarthy MV, Zhu Y, Lopez M. Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis. J Clin Invest 2007, 117:2539-2552.
36. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002, 128:159-168.
37. Finck BN, Han X, Courtois M. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 2003, 100:1226-1231.
38. Finck BN, Lehman JJ, Leone TC. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109:121-130.
39. Pamplona R, Portero-Otin M, Ruiz C. Double bond content of phospholipids and lipid peroxidation negatively correlate with maximum longevity in the heart of mammals. Mech Ageing Dev 2000, 112:169-183.
40. Pamplona R, Prat J, Cadenas S. Low fatty acid unsaturation protects against lipid peroxidation in liver mitochondria from long-lived species: the pigeon and human case. Mech Ageing Dev 1996, 86:53-66.
41. Burkart EM, Sambandam N, Han X. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 2007, 117:3930-3939.